Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 29 Mar 2018

Cancer Trial Halted in the UK After Overdosing First Patient

Redx Pharma has temporarily interrupted recruitment in a Phase I/IIa cancer trial following “significant adverse events” of its drug on the first patient treated. The first time Redx Pharma’s cancer drug RXC004 has been tested in a patient has resulted in adverse side effects. According to Redx, the dose tested resulted in a higher exposure […]

March 29, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

tigenix alofisel takeda stem cell therapy crohns disease

News and Trends 27 Mar 2018

Stem Cell Therapy for Crohn’s Disease Approved in Europe

Developed by TiGenix, Alofisel is the first stem cell therapy made out of donor stem cells to receive a marketing authorization in Europe. The European Commission has approved Alofisel (darvadstrocel), a stem cell therapy to treat complex perianal fistulas — one of the most disabling complications of Crohn’s disease. The cell therapy represents an alternative to multiple surgeries […]

March 27, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 26 Mar 2018

Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II

GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in patients with multiple sclerosis by going after an unusual target: a virus that has been in our genome since ancient times. Paris-based biotech GeNeuro has reported that a treatment it is developing in partnership with Servier has potential to treat […]

March 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 26 Mar 2018

The 10 Biotech Venture Capital Firms in Europe to Watch in 2018

Who’s funding the biotech industry in Europe? I’ve gathered a list of some of the most active European biotech venture capital firms that will be setting the pace of the industry this year. Biotech can do great things, from curing deadly diseases to helping make the plastics industry more sustainable. But there is a common […]

March 26, 2018 - 7 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Mar 2018

Oxford Firm Develops Better Test for ALS Diagnosis

Oxford BioDynamics has presented data from a new diagnostic test that could help not just diagnose ALS but also help patients get a personalized treatment. Amyotrophic lateral sclerosis (ALS) is a motor neuron disease whose diagnosis comes with the hard news that most patients die merely within 3 to 5 years of diagnosis. One of […]

March 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 20 Mar 2018

Why It’s the Best Time to Be in Cell and Gene Therapy

Cell and gene therapies are here, and they’re here to stay. We stopped to chat about the future of the field with Alexander Vos last week at Bio Europe Spring. The cell and gene therapy space has been given a big boost in the last couple of years. Since 2016, GSK’s gene therapy Strimvelis is available […]

March 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

lundbeck prexton therapeutics acquisition parkinsons

News and Trends 16 Mar 2018

Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

Lundbeck is acquiring Prexton Therapeutics in a deal that could reach up to €905M if the Swiss company’s Parkinson’s treatment proves successful. Danish pharma Lundbeck has decided to boost its pipeline with the acquisition of Prexton Therapeutics. The deal grants Lundbeck with global rights to foliglurax, a drug to reduce the “off” time periods when Parkinson’s motor […]

March 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

sofinnova partners industrial biotech fund

News and Trends 15 Mar 2018

French VC Raises the Biggest Green Biotech Fund in the World

Update (15/03/2018): Sofinnova Partners has closed its fund Industrial Biotech I at €125M, making it the largest fund dedicated to driving the transition towards a more sustainable fund. 03/03/2017 Sofinnova Partners has announced the first closing of a new fund, dedicated to renewable chemistry in industrial biotech, at €106 million. The largest biotech VC in […]

March 15, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Mar 2018

A New Drug for Atrial Fibrillation Starts Human Testing in Europe

Update (14/03/2018): Acesion Pharma has started a Phase I clinical trial at the Centre for Human Drug Research (CHDR) in the Netherlands. The trial will test AP30663, a treatment for atrial fibrillation that the company believes has the potential to work better than every option currently available. Originally published on 2/8/2018 The Danish biotech Acesion Pharma […]

March 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 12 Mar 2018

A Dutch Company on the Quest Against Cystic Fibrosis

ProQR is the result of a personal quest against cystic fibrosis started by its CEO, Daniel de Boer. Interested in his story and the company’s unique approach to treating the disease using RNA technology, I decided to speak with him. Daniel de Boer founded ProQR in 2012 following a strong determination to improve the lives […]

March 12, 2018 - 6 minutesmins - By Clara Rodríguez Fernández

evotec sanofi infectious disease pipeline

More News! 8 Mar 2018

Evotec Takes Over Sanofi’s Infectious Disease Pipeline

Evotec will be getting over 10 assets, €60M upfront and about 100 scientists from Sanofi’s infectious disease research unit to work on developing new antimicrobials. Evotec has entered exclusive negotiations with Sanofi to accelerate infectious disease R&D through a new innovation platform located near Lyon, France, that will be open to academia, private companies, foundations and government agencies. Sanofi, […]

March 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

bone therapeutics spinal fusion cell therapy

News and Trends 8 Mar 2018

Belgian Firm Raises €19M to Fix Spinal Fusion with Cell Therapy

Bone Therapeutics has raised €19.5M through a private placement that will fund the completion of clinical trials testing its cell therapy for spinal fusion and other bone diseases. Based in Groselies, Belgium, Bone Therapeutics wants to use cell therapy to help people with bone injuries or diseases regenerate healthy bone. In order to complete its […]

March 8, 2018 - 1 minutemin - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us